US Venture Capital Outlook 2027 — The Missing Cohort Arrives

This is a forward-looking outlook written from a mid-2026 vantage point about a year that has not begun. Every statement below is a scenario or a monitoring question. None should be read as a forecast.

The defining feature of the US venture market in 2027 is an absence, and the arithmetic behind it is not in dispute.

Seed formation outside favoured themes was constrained from 2022 through 2025. The US Venture Capital Report 2022 traces the origin to the LP channel: seed funds raising in that period found the market harder, and smaller funds deploy less capital into fewer companies.

Companies funded at seed reach Series A two to three years later and Series B four to five. So the 2022 and 2023 seed cohorts should be raising Series B in 2027, and there are fewer of them than a normal cycle would produce.

The Series A effect already arrived, in 2025 and 2026, and the 2026 outlook describes it producing rising prices on falling deal count.

2027 is where it compounds, and the compounding is the part that is under-appreciated. Attrition between stages is roughly constant in percentage terms. A thin Series A cohort therefore produces a proportionally thin Series B cohort, and the absolute shortfall grows at each stage because the same attrition rate applied to a smaller base leaves fewer survivors.

The consequence is a market that will look strong and will be thin. Growth capital is available. The population of companies that have reached growth-stage milestones is smaller than usual. Too much capital chasing too few qualifying assets raises prices — which is reported as a recovery and is a supply shortage.

No decision made in 2027 changes this. Companies that were not funded in 2022 do not exist. Even full recovery in seed formation now produces Series B companies in 2031. This is a year for reading the market correctly rather than for acting on it, which is an unusual and uncomfortable position.

Why the gap compounds rather than persisting

The compounding mechanism deserves precise treatment because it is the difference between a gap that fades and one that worsens.

Attrition between stages is roughly proportional. Of companies that raise a seed round, some fraction reaches Series A; of those, some fraction reaches Series B. Those fractions vary by cycle and are broadly stable in structure.

Apply a constant rate to a smaller base and the absolute shortfall grows:

Suppose a normal cohort is 1,000 seed companies, with 40% reaching Series A and 50% of those

reaching Series B — 400 at A, 200 at B. Now suppose seed formation falls 30%, to 700 companies.

At the same rates: 280 at Series A, 140 at Series B.

The seed shortfall was 300 companies. The Series A shortfall is 120. The Series B shortfall is

60. **In percentage terms the gap is constant at 30% — but the market at Series B is

competing over 140 companies instead of 200, and the capital pool did not shrink 30%.**

*Derived: illustrative arithmetic with round numbers and constant graduation rates, chosen to

expose the mechanism. Not a description of any actual cohort.*

The capital side is the part that does not shrink proportionally. Funds raised in 2021 and 2022 with growth mandates still need to deploy. Reserve pressure has partly resolved as portfolios were triaged. So the capital available at Series B in 2027 is not 30% smaller — and the companies are.

That is the entire mechanism behind the price effect, and it is arithmetic rather than sentiment.

Two further compounding effects:

• Quality selection is weaker, not stronger. A thin cohort means investors have fewer companies to choose between, which means the marginal funded company is worse than in a broad cohort even as prices rise.
• The best companies are more competed. Concentration of capital onto fewer assets raises prices most for the assets that would have raised easily anyway.

Reading the data correctly

The 2027 data will support two opposite conclusions and only one will be right. The diagnostic is available and cheap.

What will be reported: Series B valuations rising. Round sizes rising. Time to close shortening. Competitive dynamics returning. Every one of these is consistent with a recovery.

What must be checked alongside it:

• Deal count, against a 2019–2021 baseline rather than against 2023–2026. A recovery relative to a constrained year is not a recovery. This is the single most important correction and it is routinely omitted.
• The ratio of capital available to companies qualifying, which is the actual variable. Rising prices with rising count is demand strength; rising prices with falling count is a supply shortage.
• Graduation rates, which Carta publishes free by cohort. If the share of seed companies reaching Series A and B has held while the absolute numbers fell, the cause is cohort size rather than company quality.
• Median versus mean round size. In a concentrated market the mean is pulled by the largest rounds; the divergence between them measures how concentrated the market has become.

The stakes of getting this wrong are asymmetric. An investor who reads a supply shortage as demand strength deploys into a thin market at inflated prices, which is the 2021 error in a different form. An investor who reads it correctly deploys more slowly and accepts lower deployment in a period that feels attractive — which is the archive's most consistently recurring recommendation and its least comfortable one.

The years that feel best to deploy in are, mechanically, the years with the highest prices. In 2027 the price will be high for a reason that has nothing to do with the companies being better.

The 2021 vintage should be resolved

An improvement in data quality should arrive in 2027, and it is worth naming because it partly offsets the difficulty above.

The situation. The 2026 outlook describes the 2021 vintage reaching its terminal year: positions deferred through bridges, extensions, restructurings and continuation discussions since 2022 face structural deadlines as funds approach the end of their lives.

By 2027 most of that should have resolved, in one direction or another:

• Exits at achievable prices, accepting what the market provides.
• Continuation vehicles, where the asset is attractive enough for new buyers.
• Restructurings, where existing investors fund a reset.
• Wind-downs, where none of the above works.

Why resolution improves the data even when the outcomes are poor:

• Marks reflect transactions rather than estimates. A portfolio where every uncertain position has resolved can be assessed; one where they have all been deferred cannot.
• The measurement gap narrows. The US Venture Capital Report 2023 describes shutdowns, quiet sales and restructurings being largely absent from funding data. Once resolved, they are at least historically countable.
• Vintage performance becomes assessable. The 2021 vintage's actual return, rather than its carrying value, becomes estimable — which matters for every allocation decision that benchmarks against it.
• Manager assessment improves. A manager's handling of a difficult vintage is informative, and it can only be assessed once the vintage has resolved.

The uncomfortable corollary is that resolution will make the data look worse before it makes it useful. More shutdowns recorded, more sales below prior marks, and reported vintage returns falling as carrying values meet realisations. That is the data becoming honest rather than the situation deteriorating, and the two will be difficult to distinguish in commentary.

Composition change is permanent

A change to the industry's structure occurred between 2022 and 2026 that does not reverse on any 2027 timeline.

What changed, per the US Venture Capital Reports 2024 and 2025:

• First-time fund formation fell sharply, as LPs prioritised re-ups with limited new commitment capacity.
• Deployment concentrated into the largest platforms, whose structural advantages — multi-stage capability, fundraising ease, permanent capital, brand as an access asset — reinforce one another.
• Small specialist funds shrank or disappeared, and the specialised early-stage capacity that existed in 2021 does not reappear when conditions improve.

Why this does not reverse quickly:

• A manager who could not raise a first fund in 2023 does not raise a third in 2033. The pipeline of established managers a decade out is determined by first funds now.
• The advantages of scale compound. A larger firm raises more easily, wins more competitive rounds, and builds more brand — which makes it easier to raise again.
• LP capacity for relationships is finite. An institution supporting twenty managers cannot support forty, and the incumbents hold the slots.

Why it matters beyond any individual firm's returns. Venture capital's economic function is to fund heterogeneous bets on uncertain outcomes, which requires many independent decision-makers with different views. Concentration reduces the number of independent views, and the effect on what gets funded is not visible in any aggregate statistic.

The indicator to watch is first-time fund formation, reported separately and free by NVCA/PitchBook. A recovery there is the earliest signal that the composition change is reversing; its absence is the signal that it is not.

What would change the picture

Evidence the cohort gap is at its worst rather than easing: Series B deal count against a 2019–2021 baseline, alongside median valuations. Rising prices on falling count is the signature, and both series are free.

Evidence seed formation is repairing: seed deal count rising, not seed deal value. Value can rise on concentration and tells you nothing about how many companies were funded. Carta publishes count free and quarterly.

Evidence the 2021 vintage has resolved: shutdown counts, secondary volume and reported vintage returns converging toward realisations. Expect this to look like deterioration and to be an improvement in honesty.

Evidence the composition change is reversing: first-time fund formation rising, reported separately by NVCA/PitchBook. This is the cleanest indicator of whether the manager pipeline is repairing.

Evidence exits are normalising: distributions as a percentage of net asset value moving toward long-run averages. Still the highest-leverage variable, still routinely measured with the wrong statistic.

Evidence the AI capital cycle is resolving: per the Global Investment Outlook 2027, watch the layers separately. The aggregate will average partial outcomes into something that describes none of them.

What an allocator could act on

Fix the baseline before reading anything. Series B deal count in 2027 should be compared against 2019–2021, not against 2023–2026. A recovery relative to a constrained year is not a recovery, and this single correction determines whether the year's data reads as strength or as shortage.

Read count and value together, always. Rising valuations with rising deal count is demand strength. Rising valuations with falling deal count is a supply shortage. They are indistinguishable in valuation data and unambiguous in count data, and only one of the two series gets reported.

Check graduation rates to isolate the cause. If the share of seed companies reaching Series A and B has held while the absolute numbers fell, the cause is cohort size rather than company quality. Carta publishes graduation rates free by cohort, which is rare and is exactly the series this question needs.

Accept lower deployment in a market that feels attractive. Entry price is the dominant determinant of a vintage's return and is fixed at the decision point. A thin market with rising prices is the 2021 error in a different form, and the only defence is pacing discipline that will look wrong for a period.

Expect the data to get worse and better simultaneously. As the 2021 vintage resolves, more shutdowns and below-mark sales will be recorded and reported vintage returns will fall toward realisations. That is the data becoming honest, not the situation deteriorating, and the two will be hard to distinguish in commentary.

Watch first-time fund formation as the composition indicator. NVCA/PitchBook reports it separately and free. It is the cleanest signal of whether the manager pipeline is repairing, and its absence tells you the concentration described in 2024 and 2025 is compounding rather than reversing.

Assess large-platform allocations on what they actually deliver. Access and durability are genuine. A return profile resembling an index of the asset class is not what venture fees are paid for, and the distinction should be explicit rather than assumed.